Table 3.
In sensitivity analysis (use of more sensitive optic neuritis case-finding algorithms): crude incidence of optic neuritis in patients who initiate anti-TNF or non-biologic DMARD therapy by inflammatory disease indication
| Current User Analysis | Current and Past User Analysis | |||
|---|---|---|---|---|
|
| ||||
| Person-Years | Rate* (per 100,000 person-years) | Person-Years | Rate+ (per 100,000 person-years) | |
| Rheumatoid arthritis | ||||
| Non biologic DMARD | 0 | 0 | 23750 | 21.1 (8.8, 50.6) |
| Anti-TNF new users | 22461 | 8.9 (2.2, 35.6) | 51334 | 9.7 (4.1, 23.6) |
|
| ||||
| IBD | ||||
| AZA/6MP | 4608 | 0 | 14509 | 6.9 (1.0, 48.9) |
| Anti-TNF new users | 2319 | 43 (6.1, 306) | 7437 | 26.9 (6.7, 107.5) |
|
| ||||
| PsO, PsA, AS | ||||
| Non biologic DMARD | 4119 | 0 | 17706 | 22.6 (8.5,60.2) |
| Anti-TNF new users | 3963 | 0 | 8620 | 0 |
|
| ||||
| Across all indications | ||||
| Non- biologic DMARD | 15799 | 6.3 (0.9, 44.9) | 55964 | 17.9 (9.6, 33.2) |
| Anti-TNF new users | 28743 | 10.4 (3.4,32.2) | 67392 | 10.4 (4.9, 21.8) |
*
“Current user” analysis in which exposure stops at drug stop
+
“Current and past user” analysis in which exposure continues for 365 days after drug start until new exposure occurs TNF = tumor necrosis factor; DMARD=disease-modifying anti rheumatic drug; AZA=azathioprine; 6MP=6 mercaptopurine
Note: rules associated with use of Medicare data preclude including case numbers within tables when cell values are less than 11